Enzo Biochem, Inc. (NYSE:ENZ) Files An 8-K Other EventsItem 8.01 Other events
On December 3, 2018, Enzo Biochem, Inc. issued a press release titled “Enzo Biochem Reports Publication of Study on Therapeutic Candidate SK1-I Detailing Promising Results in a Model of Treatment Resistant Breast Cancer.”
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| 99.1 | Press Release of Enzo Biochem, Inc., dated December 3, 2018. |
ENZO BIOCHEM INC ExhibitEX-99.1 2 c92426_ex99-1.htm Exhibit 99.1 Enzo Biochem,…To view the full exhibit click here
About Enzo Biochem, Inc. (NYSE:ENZ)
Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women’s health infectious agents, as well as for use in the identification of pathogens for other markets.
